本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Akebia Therapeutics, Inc.

1.76
+0.09005.39%
盘后1.760.00000.00%16:45 EST
成交量:618.42万
成交额:1,089.57万
市值:4.67亿
市盈率:-27.16
高:1.84
开:1.69
低:1.67
收:1.67
52周最高:4.08
52周最低:1.52
股本:2.65亿
流通股本:2.60亿
量比:0.71
换手率:2.38%
股息:- -
股息率:- -
每股收益(TTM):-0.0648
每股收益(LYR):-0.3290
净资产收益率:-553.45%
总资产收益率:4.80%
市净率:11.23
市盈率(LYR):-5.35

数据加载中...

2024/03/14

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/03/14

重要事件披露

Form 8-K - Current report
2024/03/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/28

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/28

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/28

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/28

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/13

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/13

重要事件披露

Form 8-K - Current report
2024/02/09

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/01/30

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/01/30

重要事件披露

Form 8-K - Current report
2024/01/08

重要事件披露

Form 8-K - Current report
2024/01/08

重要事件披露

Form 8-K - Current report
2023/12/18

重要事件披露

Form 8-K - Current report